July 26, 2016 08:45 AM EDT
R&D

J&J joins the com­bo line­up at Bris­tol-My­ers, where a new wag­on mas­ter runs on­col­o­gy R&D

John Carroll

Editor & Founder

J&J is tak­ing an im­muno-on­col­o­gy drug li­censed in from Aduro and match­ing it with Bris­tol-My­ers Squibb’s pi­o­neer­ing check­point drug Op­di­vo in the lat­est ex­am­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times